JP6396313B2 - 操作された単量体抗体断片 - Google Patents

操作された単量体抗体断片 Download PDF

Info

Publication number
JP6396313B2
JP6396313B2 JP2015546121A JP2015546121A JP6396313B2 JP 6396313 B2 JP6396313 B2 JP 6396313B2 JP 2015546121 A JP2015546121 A JP 2015546121A JP 2015546121 A JP2015546121 A JP 2015546121A JP 6396313 B2 JP6396313 B2 JP 6396313B2
Authority
JP
Japan
Prior art keywords
polypeptide
monomeric
linked
amino acid
engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015546121A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505559A (ja
JP2016505559A5 (https=
Inventor
ドゥアン ウェイリー
ドゥアン ウェイリー
ダブリュー． クリッツ ロナルド
ダブリュー． クリッツ ロナルド
テツヤ イシノ
テツヤ イシノ
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2016505559A publication Critical patent/JP2016505559A/ja
Publication of JP2016505559A5 publication Critical patent/JP2016505559A5/ja
Application granted granted Critical
Publication of JP6396313B2 publication Critical patent/JP6396313B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015546121A 2012-12-07 2013-11-25 操作された単量体抗体断片 Expired - Fee Related JP6396313B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261734841P 2012-12-07 2012-12-07
US61/734,841 2012-12-07
PCT/IB2013/060384 WO2014087299A1 (en) 2012-12-07 2013-11-25 Engineered monomeric antibody fragments

Publications (3)

Publication Number Publication Date
JP2016505559A JP2016505559A (ja) 2016-02-25
JP2016505559A5 JP2016505559A5 (https=) 2017-01-12
JP6396313B2 true JP6396313B2 (ja) 2018-09-26

Family

ID=50001048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015546121A Expired - Fee Related JP6396313B2 (ja) 2012-12-07 2013-11-25 操作された単量体抗体断片

Country Status (6)

Country Link
US (1) US10233229B2 (https=)
EP (1) EP2928917B1 (https=)
JP (1) JP6396313B2 (https=)
CA (1) CA2892756C (https=)
ES (1) ES2664095T3 (https=)
WO (1) WO2014087299A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015074063A1 (en) * 2013-11-18 2015-05-21 University Of Maryland, Baltimore Hyper-glycosylated antibodies with selective fc receptor binding
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
EA201892249A1 (ru) 2016-04-04 2019-05-31 Шайр Хьюман Дженетик Терапиз, Инк. Конъюгированный ингибитор c1-эстеразы и пути его применения
JP7556687B2 (ja) 2017-02-24 2024-09-26 中外製薬株式会社 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法
WO2019023097A1 (en) * 2017-07-26 2019-01-31 Smet Pharmaceutical Inc ASYMMETRIC BISPECIFIC ANTIBODIES AND THEIR USE
WO2020221450A1 (en) * 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies and methods for treatment of influenza a infection

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
KR100545720B1 (ko) * 2004-05-31 2006-01-24 메덱스젠 주식회사 당화된 면역글로불린 및 이를 포함하는 면역접합체
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US20110045007A1 (en) 2007-05-31 2011-02-24 Genmab A/S Fusion or linked proteins with extended half life
CA2766166A1 (en) 2009-07-08 2011-01-13 Amgen Inc. Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering
US20120276092A1 (en) * 2009-10-29 2012-11-01 Jinquan Luo Antibody Glycosylation Variants
ES2688978T3 (es) 2009-11-23 2018-11-07 Amgen Inc. Anticuerpo monomérico Fc

Also Published As

Publication number Publication date
ES2664095T3 (es) 2018-04-18
US20150322135A1 (en) 2015-11-12
CA2892756A1 (en) 2014-06-12
CA2892756C (en) 2020-04-14
JP2016505559A (ja) 2016-02-25
EP2928917A1 (en) 2015-10-14
EP2928917B1 (en) 2018-02-28
WO2014087299A9 (en) 2015-08-27
US10233229B2 (en) 2019-03-19
WO2014087299A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
JP6433950B2 (ja) ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法
CA3092456C (en) Anti-tigit antibody and use thereof
CN107849136B (zh) 抗TfR抗体及其在治疗增殖性和炎性疾病中的用途
JP7504027B2 (ja) 互いに連結された２つの抗原結合ドメインを含む抗原結合分子
JP2019534845A (ja) マクロファージ上のＦｃ受容体結合の破壊による抗ＳｌＲＰα抗体療法の効果増強
JP6396313B2 (ja) 操作された単量体抗体断片
CN114466663B (zh) 以FcRn拮抗剂治疗抗体介导的障碍的方法
WO2016109415A1 (en) Anti-cd47 antibodies and uses thereof
US12448449B2 (en) Immune targeting molecules and uses thereof
JP2022525275A (ja) ヘテロ多量体タンパク質及びその使用法
JP2023548109A (ja) デルタガンマ鎖媒介性免疫を調節するための組成物及び方法
CA2891764A1 (en) Recombinant bispecific antibody binding to cd20 and cd95
TW202144416A (zh) 用於調節δ鏈介導之免疫的材料及方法
KR20220145854A (ko) 지방산 분자와 접합된 항체 및 이의 용도
US20240124574A1 (en) Bispecific Antibodies with Charge Pairs and Uses Thereof
US20190177425A1 (en) Humanized and chimeric monoclonal antibodies to cd81
JP2024544924A (ja) トランスサイレチン（ｔｔｒ）単量体結合抗体
AU2022377084A1 (en) Compositions and methods for the modulation of beta chain-mediated immunity
JP2025528101A (ja) 多重特異性ポリペプチド複合体
CN117015556A (zh) 带电荷对的双特异性抗体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180410

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180813

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180829

R150 Certificate of patent or registration of utility model

Ref document number: 6396313

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees